Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BTD vs BCD in AL Amyloidosis
NCT04612582Phase 4Unknown
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Jan 2020
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of thalidomide in immunoglobulin light chain amyloidosis (2 arms), sponsored by Guangdong Provincial People's Hospital. Primary endpoint: Hematologic Response (CR and VGPR) at 1 year. Status: unknown.
02
Drugs
thalidomide
03
Conditions
immunoglobulin light chain amyloidosis
Beyond the preview
Go deeper on NCT04612582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04612582.